Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 11 | 2023 | 57 | 3.060 |
Why?
|
| Cardiovascular Diseases | 13 | 2025 | 166 | 2.640 |
Why?
|
| Heart Failure | 5 | 2023 | 77 | 1.660 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2023 | 5 | 1.560 |
Why?
|
| Aortic Valve Stenosis | 2 | 2023 | 6 | 1.550 |
Why?
|
| Myocardial Infarction | 7 | 2023 | 64 | 1.380 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 34 | 1.320 |
Why?
|
| Humans | 51 | 2025 | 12240 | 1.290 |
Why?
|
| Female | 39 | 2025 | 6974 | 1.290 |
Why?
|
| Risk Factors | 16 | 2024 | 1049 | 1.190 |
Why?
|
| Sex Characteristics | 5 | 2023 | 64 | 1.170 |
Why?
|
| Women's Health | 3 | 2020 | 88 | 1.150 |
Why?
|
| Hospital Mortality | 5 | 2023 | 72 | 1.100 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 25 | 0.920 |
Why?
|
| Male | 25 | 2023 | 6815 | 0.870 |
Why?
|
| Quality of Life | 4 | 2023 | 261 | 0.850 |
Why?
|
| Myocardial Ischemia | 2 | 2022 | 24 | 0.850 |
Why?
|
| Pacemaker, Artificial | 2 | 2023 | 4 | 0.820 |
Why?
|
| Sex Factors | 7 | 2022 | 229 | 0.810 |
Why?
|
| Terminal Care | 1 | 2023 | 12 | 0.760 |
Why?
|
| Health Status Disparities | 2 | 2019 | 30 | 0.730 |
Why?
|
| Cognitive Dysfunction | 4 | 2025 | 449 | 0.720 |
Why?
|
| Defibrillators, Implantable | 2 | 2021 | 5 | 0.710 |
Why?
|
| Aged | 19 | 2025 | 4000 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 22 | 0.690 |
Why?
|
| Pregnancy Complications, Cardiovascular | 5 | 2021 | 11 | 0.670 |
Why?
|
| Coronavirus | 1 | 2021 | 2 | 0.670 |
Why?
|
| Cardiologists | 1 | 2020 | 2 | 0.630 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 3 | 0.630 |
Why?
|
| Exercise | 3 | 2025 | 233 | 0.630 |
Why?
|
| Endothelium | 1 | 2020 | 5 | 0.620 |
Why?
|
| Vascular Diseases | 1 | 2020 | 25 | 0.620 |
Why?
|
| Hospitalization | 5 | 2021 | 158 | 0.610 |
Why?
|
| Stroke | 7 | 2021 | 117 | 0.610 |
Why?
|
| Patient Care Management | 2 | 2021 | 11 | 0.610 |
Why?
|
| Betacoronavirus | 1 | 2020 | 38 | 0.600 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2019 | 6 | 0.600 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 19 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 45 | 0.590 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 48 | 0.590 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 3 | 0.570 |
Why?
|
| Women's Health Services | 1 | 2018 | 6 | 0.560 |
Why?
|
| United States | 14 | 2021 | 989 | 0.560 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 14 | 0.560 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 23 | 0.560 |
Why?
|
| Middle Aged | 14 | 2024 | 4043 | 0.530 |
Why?
|
| Age Factors | 5 | 2021 | 350 | 0.510 |
Why?
|
| Risk Assessment | 5 | 2021 | 295 | 0.470 |
Why?
|
| Treatment Outcome | 7 | 2025 | 1478 | 0.460 |
Why?
|
| Social Support | 1 | 2016 | 98 | 0.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 79 | 0.450 |
Why?
|
| Cognition | 4 | 2025 | 641 | 0.440 |
Why?
|
| Physicians, Women | 2 | 2022 | 11 | 0.350 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2022 | 2 | 0.330 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2022 | 5 | 0.330 |
Why?
|
| Cardiology | 2 | 2021 | 26 | 0.320 |
Why?
|
| Cardiovascular System | 2 | 2021 | 3 | 0.320 |
Why?
|
| Biomarkers | 4 | 2025 | 294 | 0.310 |
Why?
|
| Cardiovascular Agents | 2 | 2021 | 17 | 0.310 |
Why?
|
| Prognosis | 3 | 2021 | 363 | 0.310 |
Why?
|
| Patient Readmission | 2 | 2019 | 48 | 0.280 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 195 | 0.260 |
Why?
|
| Adult | 6 | 2022 | 3557 | 0.240 |
Why?
|
| Pregnancy | 6 | 2021 | 193 | 0.230 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2022 | 5 | 0.220 |
Why?
|
| Coronary Artery Disease | 2 | 2020 | 56 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2022 | 1467 | 0.220 |
Why?
|
| Risk Adjustment | 2 | 2021 | 4 | 0.210 |
Why?
|
| Leadership | 2 | 2022 | 55 | 0.210 |
Why?
|
| Illinois | 2 | 2021 | 110 | 0.210 |
Why?
|
| American Heart Association | 2 | 2021 | 6 | 0.200 |
Why?
|
| Pulmonary Veins | 1 | 2023 | 6 | 0.200 |
Why?
|
| Aortic Valve | 1 | 2023 | 9 | 0.200 |
Why?
|
| Minority Groups | 1 | 2023 | 40 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 36 | 0.200 |
Why?
|
| Electric Countershock | 3 | 2006 | 6 | 0.200 |
Why?
|
| Societies, Medical | 2 | 2020 | 48 | 0.190 |
Why?
|
| Death | 1 | 2023 | 24 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 116 | 0.190 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2022 | 6 | 0.180 |
Why?
|
| Palliative Care | 1 | 2023 | 53 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 2152 | 0.180 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 18 | 0.180 |
Why?
|
| Sotalol | 1 | 2021 | 1 | 0.180 |
Why?
|
| Logistic Models | 2 | 2021 | 196 | 0.180 |
Why?
|
| Coronary Circulation | 2 | 2020 | 14 | 0.180 |
Why?
|
| Troponin | 1 | 2021 | 10 | 0.170 |
Why?
|
| Sexism | 1 | 2021 | 5 | 0.170 |
Why?
|
| Shock, Cardiogenic | 1 | 2021 | 3 | 0.170 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 6 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2021 | 3 | 0.170 |
Why?
|
| Hormones | 1 | 2021 | 7 | 0.170 |
Why?
|
| Ventricular Fibrillation | 1 | 2021 | 11 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 12 | 0.170 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 12 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 38 | 0.170 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 36 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 100 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 7 | 0.160 |
Why?
|
| Comorbidity | 1 | 2021 | 209 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2020 | 7 | 0.160 |
Why?
|
| Postnatal Care | 1 | 2020 | 6 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 9 | 0.160 |
Why?
|
| Catheter Ablation | 1 | 2020 | 21 | 0.160 |
Why?
|
| Radiation-Protective Agents | 1 | 2020 | 3 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2021 | 119 | 0.160 |
Why?
|
| Colchicine | 1 | 2020 | 6 | 0.150 |
Why?
|
| Electrocardiography | 2 | 2006 | 47 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2020 | 15 | 0.150 |
Why?
|
| Global Health | 1 | 2019 | 11 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 33 | 0.150 |
Why?
|
| Sex Distribution | 1 | 2019 | 34 | 0.150 |
Why?
|
| After-Hours Care | 1 | 2019 | 1 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 20 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 40 | 0.150 |
Why?
|
| Heart | 1 | 2019 | 42 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 126 | 0.150 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1998 | 8 | 0.140 |
Why?
|
| Treatment Refusal | 1 | 2018 | 8 | 0.140 |
Why?
|
| Heart Transplantation | 1 | 1998 | 14 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 94 | 0.140 |
Why?
|
| Graft Rejection | 1 | 1998 | 30 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 100 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 25 | 0.140 |
Why?
|
| Prevalence | 1 | 2018 | 175 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2018 | 77 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 546 | 0.130 |
Why?
|
| Echocardiography | 4 | 2023 | 35 | 0.130 |
Why?
|
| Life Style | 2 | 2020 | 102 | 0.130 |
Why?
|
| Diet Surveys | 1 | 2017 | 12 | 0.130 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 19 | 0.130 |
Why?
|
| Heart Atria | 1 | 1996 | 13 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2017 | 27 | 0.120 |
Why?
|
| Young Adult | 2 | 2017 | 863 | 0.120 |
Why?
|
| Self Efficacy | 1 | 2016 | 30 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 38 | 0.120 |
Why?
|
| Health Status | 1 | 2016 | 96 | 0.110 |
Why?
|
| Hypertension | 3 | 2020 | 85 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 182 | 0.110 |
Why?
|
| Smoking | 2 | 2018 | 84 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2022 | 827 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2013 | 27 | 0.100 |
Why?
|
| Adolescent | 1 | 2016 | 989 | 0.100 |
Why?
|
| Registries | 3 | 2022 | 88 | 0.090 |
Why?
|
| Neuropsychological Tests | 2 | 2025 | 558 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 111 | 0.090 |
Why?
|
| Health Promotion | 1 | 2013 | 78 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 41 | 0.090 |
Why?
|
| Motor Activity | 1 | 2013 | 175 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 1990 | 17 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 400 | 0.070 |
Why?
|
| Time Factors | 3 | 2021 | 695 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 156 | 0.070 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2021 | 14 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2004 | 12 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 128 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 19 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 2 | 0.050 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2022 | 13 | 0.050 |
Why?
|
| Flecainide | 1 | 2021 | 1 | 0.040 |
Why?
|
| Recurrence | 2 | 2006 | 126 | 0.040 |
Why?
|
| Tachycardia | 1 | 2021 | 6 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2000 | 256 | 0.040 |
Why?
|
| Peripartum Period | 1 | 2021 | 2 | 0.040 |
Why?
|
| Pregnancy, High-Risk | 1 | 2021 | 2 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 89 | 0.040 |
Why?
|
| Lactation | 1 | 2021 | 33 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 8 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2020 | 25 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 1 | 0.040 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2020 | 1 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 4 | 0.040 |
Why?
|
| Menopause, Premature | 1 | 2020 | 3 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 55 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 16 | 0.040 |
Why?
|
| Sleep Apnea, Central | 1 | 2000 | 26 | 0.040 |
Why?
|
| Heart Rate | 1 | 2000 | 55 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 6 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 15 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2000 | 38 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 423 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 10 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 338 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2019 | 30 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2019 | 19 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 82 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 126 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 13 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 15 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2018 | 9 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 78 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2018 | 83 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 95 | 0.030 |
Why?
|
| Diet, Western | 1 | 2017 | 5 | 0.030 |
Why?
|
| Obesity | 1 | 2018 | 156 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 324 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 221 | 0.030 |
Why?
|
| Animals | 1 | 2020 | 2092 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 1996 | 726 | 0.030 |
Why?
|
| Prospective Studies | 1 | 1996 | 817 | 0.030 |
Why?
|
| Social Networking | 1 | 2013 | 7 | 0.020 |
Why?
|
| Efficiency | 1 | 2013 | 13 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 46 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 66 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 55 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 453 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 60 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 161 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2004 | 30 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 143 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2000 | 6 | 0.010 |
Why?
|
| Respiration | 1 | 2000 | 15 | 0.010 |
Why?
|
| Tracheostomy | 1 | 2000 | 9 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2000 | 14 | 0.010 |
Why?
|
| Anesthesia | 1 | 2000 | 19 | 0.010 |
Why?
|
| Child | 1 | 2000 | 614 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1991 | 4 | 0.010 |
Why?
|
| Equipment Design | 1 | 1991 | 76 | 0.010 |
Why?
|